regardless of encouraging clinical data, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is experiencing substantial difficulty from managed care entities. The companies are typically building obstacles to reimbursement, such as steep cost requirements and approval processes that hinder patient availabilit